Publication | Closed Access
BIBR-1048 Boehringer Ingelheim.
29
Citations
0
References
2002
Year
PharmacotherapyThrombosisVenous ThrombosisStrokeHematologyClinical TrialsIso Management StandardThrombin InhibitorPublic HealthPlatelet AntagonistLaboratory MedicineAtherosclerosisAtrial FibrillationBibr-1048 Boehringer IngelheimPharmacologyCardiovascular DiseaseHemostasisCoagulopathyMedicineAnticoagulantBoehringer Ingelheim
BIBR-1048, a thrombin inhibitor and an orally-active prodrug of BIBR-953ZW, is under development by Boehringer Ingelheim as a potential antithrombotic agent [331881]. By 1999, BIBR-1048 was in phase II clinical trials for thromboembolism and the prevention of stroke due to atrial fibrillation [331881]; by April 2002, proof-of-principle had been demonstrated in phase II trials in deep vein thrombosis [446554]. In July 2001, the company revealed that an IND was expected to be filed for BIBR-953ZW in 2002 [415884].